ACOG:CA:CNSX-Alpha Cognition Inc. (CAD)

COMMON STOCK | Biotechnology |

Last Closing

USD 8.16

Change

0.00 (0.00)%

Market Cap

USD 0.05B

Volume

2.43K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
DRUG:CA Bright Minds Biosciences Inc

+0.25 (+0.43%)

USD 0.38B
METX:CA METX

+0.05 (+1.25%)

USD 0.10B
GLAB:CA Gemina Laboratories Ltd

-0.08 (-10.26%)

USD 0.05B
DTC:CA Defence Therapeutics Inc

-0.03 (-4.41%)

USD 0.03B
MDMA:CA Pharmala Biotech Holdings Inc.

+0.01 (+1.69%)

USD 0.03B
DOSE:CA Rapid Dose Therapeutics Corp

N/A

USD 0.03B
PHRM:CA PharmaTher Holdings Ltd

-0.01 (-4.55%)

USD 0.02B
TELI:CA Telescope Innovations Corp.

N/A

USD 0.02B
BIOV:CA BioVaxys Technology Corp

N/A

USD 0.01B
BETR:CA BetterLife Pharma Inc

+0.01 (+9.52%)

USD 0.01B

ETFs Containing ACOG:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -57.61% 23% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.61% 23% F 28% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 14.10% 81% B- 74% C
Dividend Return 14.10% 81% B- 74% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 89.92% 28% F 25% F
Risk Adjusted Return 15.68% 81% B- 74% C
Market Capitalization 0.05B 91% A- 95% A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.